Cladribine

Generic Name: Cladribine

Brand Names: Litak, Mavenclad

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂ClN_₅O_₃

CAS Number: 4291-63-8

Unique Ingredient Identifier: 47M74X9YT5

Background: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.

Indication: For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.

Associated Conditions: Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)

Clinical Trials

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Phase 4

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Cladribine

First Posted Date: 2019-11-26

Last Posted Date: 2024-12-02

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 40

Registration Number: NCT04178005

Locations: 🇺🇸
UT Southwestern Medical center, Dallas, Texas, United States
🇺🇸
College Park Family Care Center Physicians Group, Overland Park, Kansas, United States

Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)

Phase 3

Completed

Conditions: Multiple Sclerosis
Relapsing Multiple Sclerosis

Interventions: Biological: Rituximab
Drug: Cladribine

First Posted Date: 2019-10-09

Last Posted Date: 2024-12-16

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 267

Registration Number: NCT04121403

Locations: 🇳🇴
Department of Neurology - Drammen, Vestre Viken HF, Drammen, Buskerud, Norway
🇳🇴
Department of Neurology - Lillehammer, SI Lillehammer, Lillehammer, Oppland, Norway
🇳🇴
Department of Neurology, Stavanger universitetssykehus, Stavanger, Rogaland, Norway

and more 8 locations

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Recurrent Acute Biphenotypic Leukemia
Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Blasts 20 Percent or More of Bone Marrow Nucleated Cells
Refractory Acute Myeloid Leukemia
Refractory High Risk Myelodysplastic Syndrome
High Risk Myelodysplastic Syndrome
Recurrent High Risk Myelodysplastic Syndrome

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Idarubicin
Drug: Quizartinib

First Posted Date: 2019-08-07

Last Posted Date: 2024-12-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT04047641

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

Phase 4

Active, not recruiting

Conditions: Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis

Interventions: Drug: Cladribine

First Posted Date: 2019-05-24

Last Posted Date: 2025-03-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 47

Registration Number: NCT03963375

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 2 locations

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Cladribine

First Posted Date: 2019-05-01

Last Posted Date: 2025-04-29

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 100

Registration Number: NCT03933215

Locations: 🇺🇸
VCU Medical Center - Pediatric Neurology, Richmond, Virginia, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
HCA Research Institute, Englewood, Colorado, United States

and more 15 locations

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Cladribine Tablets

First Posted Date: 2019-05-01

Last Posted Date: 2025-04-06

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 291

Registration Number: NCT03933202

Locations: 🇺🇸
Northwest Houston Neurology, Cypress, Texas, United States
🇺🇸
VCU Medical Center - Pediatric Neurology, Richmond, Virginia, United States
🇺🇸
Sentara Ambulatory Care Center, Virginia Beach, Virginia, United States

and more 63 locations

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3

Recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: DFP-10917
Drug: Cytarabine
Drug: Azacitidine
Drug: Decitabine
Drug: Mitoxantrone
Drug: Etoposide
Drug: Fludarabine
Drug: Idarubicin
Drug: Venetoclax
Drug: Cladribine

First Posted Date: 2019-04-24

Last Posted Date: 2025-03-03

Lead Sponsor: Delta-Fly Pharma, Inc.

Target Recruit Count: 450

Registration Number: NCT03926624

Locations: 🇺🇸
University of California, Irvine, California, United States
🇺🇸
Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸
The University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 36 locations

Effects of Cladribine Tablets on the PK of Microgynon®

Phase 1

Completed

Conditions: Relapsing Multiple Sclerosis (RMS)

Interventions: Drug: Microgynon®
Drug: Cladribine
Drug: Placebo

First Posted Date: 2018-11-19

Last Posted Date: 2024-03-15

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 28

Registration Number: NCT03745144

Locations: 🇵🇱
BioVirtus Research Site Sp, Otwock, Poland
🇩🇪
St. Josef und St. Elisabeth Hospital gGmbH, Bochum, Germany
🇵🇱
M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland

and more 4 locations

Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma

Phase 2

Conditions: Non-hodgkin Lymphoma
Hodgkin Lymphoma

Interventions: Drug: Chidamide
Drug: Cladribine
Drug: gemcitabine
Drug: Busulfan
Procedure: Autologous hematopoietic stem cell transplantation

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Sichuan University

Target Recruit Count: 30

Registration Number: NCT03602131

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Myeloproliferative Neoplasm
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
High Risk Myelodysplastic Syndrome
Myeloid Sarcoma
Philadelphia Chromosome Positive

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Dexrazoxane Hydrochloride
Drug: Gemtuzumab Ozogamicin
Drug: Idarubicin

First Posted Date: 2018-07-18

Last Posted Date: 2024-12-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03589729

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy